WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
This Quarter Return
+7.52%
1 Year Return
-17.41%
3 Year Return
-27.69%
5 Year Return
+67.02%
10 Year Return
–
AUM
$2.13B
AUM Growth
+$2.13B
(-2.8%)
Cap. Flow
-$179M
Cap. Flow
% of AUM
-8.42%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
4
Reduced
1
Closed
–
Top Buys
| 1 |
Theravance Biopharma
TBPH
|
$43.3M |
| 2 |
AbbVie
ABBV
|
$36.7M |
| 3 |
Prothena Corp
PRTA
|
$35.3M |
| 4 |
Alkermes
ALKS
|
$17.5M |
| 5 |
Biogen
BIIB
|
$4.84M |
Top Sells
| 1 |
RAI
Reynolds American Inc
RAI
|
$317M |
Sector Composition
| 1 | Healthcare | 76.38% |
| 2 | Consumer Staples | 23.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $722M | 33.91% | 11,656,800 +593,500 | +5% | +$36.7M |
|
|
RAI
2
DELISTED
Reynolds American Inc
RAI
| $503M | 23.62% | 9,322,463 -5,873,650 | -39% | -$317M |
|
|
3
Prothena Corp
PRTA
$441M
| $360M | 16.93% | 10,304,751 +1,008,390 | +11% | +$35.3M |
|
|
4
Alkermes
ALKS
$4.78B
| $326M | 15.3% | 7,535,533 +404,000 | +6% | +$17.5M |
|
|
5
Theravance Biopharma
TBPH
$699M
| $198M | 9.31% | 8,733,637 +1,909,000 | +28% | +$43.3M |
|
|
NWBO
6
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
| $15.1M | 0.71% | 25,915,937 | – | – |
|
|
7
Biogen
BIIB
$19.4B
| $4.84M | 0.23% | +20,000 | New | +$4.84M |
|